New analytical monographs on TCM herbal drugs for quality proof by Wagner, Hildebert et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
New analytical monographs on TCM herbal drugs for quality proof
Wagner, Hildebert; Bauer, Rudolf; Melchart, Dieter
Abstract: Regardless of specific national drug regulations there is an international consensus that all
TCM drugs must meet stipulated high quality standards focusing on authentication, identification and
chemical composition. In addition, safety of all TCM drugs prescribed by physicians has to be guaranteed.
During the 25 years history of the TCM hospital Bad Kötzting, 171 TCM drugs underwent an analytical
quality proof including thin layer as well as high pressure liquid chromatography. As from now mass
spectroscopy will also be available as analytical tool. The findings are compiled and already published in
three volumes of analytical monographs. One more volume will be published shortly, and a fifth volume
is in preparation. The main issues of the analytical procedure in TCM drugs like authenticity, botanical
nomenclature, variability of plant species and parts as well as processing are pointed out and possible
ways to overcome them are sketched.
DOI: https://doi.org/10.1159/000444730
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-129243
Published Version
Originally published at:
Wagner, Hildebert; Bauer, Rudolf; Melchart, Dieter (2016). New analytical monographs on TCM herbal
drugs for quality proof. Forschende Komplementärmedizin, 23(Suppl 2):16-20.
DOI: https://doi.org/10.1159/000444730
Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com
Accessible online at: 
www.karger.com/fok
Komplementärmedizin
Forschende
Wissenschaft | Praxis | Perspektiven
Methodology · Methodik
Forsch Komplementmed 2016;23(suppl 2):16–20
DOI: 10.1159/000444730
New Analytical Monographs on TCM Herbal Drugs for 
Quality Proof 
Hildebert Wagner a  Rudolf Bauer b  Dieter Melchart c,d
a
 Center of Pharma Research, Department Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany 
b
 Institute of Pharmaceutical Sciences, Karl-Franzens-Universität Graz, Graz, Austria 
c
 Competence Centre for Complementary Medicine and Naturopathy, Klinikum rechts der Isar, Technische Universität München, Munich, 
  Germany 
d
 Institute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland
Schlüsselwörter
TCM-Arzneimittel · Monografie · Qualitätskontrolle ·  
Analytische Methodik
Zusammenfassung
Ungeachtet spezifischer nationaler Arzneimittelregulie-
rungen gibt es einen internationalen Konsens darüber, 
dass sämtliche TCM-Präparate verbindlichen qualitative 
hochstehenden Standards entsprechen müssen, die an 
der Echtheitsprüfung, Identifizierung und chemischen 
Komposition orientiert sind. Zudem muss die Sicherheit 
der von Ärzten verschriebenen TCM-Arzneien gewähr-
leistet sein. In der nunmehr 25-jährigen Geschichte der 
TCM-Klinik Bad Kötzting wurden 171 TCM-Präparate 
einer analytischen Qualitätsprüfung unterzogen, unter 
anderem mittels einer Dünnschichtchromatografie sowie 
einer Hochdruckflüssigkeitschromatografie. Zudem wird 
jüngst die Spektroskopie als analytisches Instrument 
eingesetzt. Die Ergebnisse dieser Testverfahren sind be-
reits zusammengefasst und in drei entsprechenden 
Bänden publiziert; weitere Publikationen sind derzeit in 
Vorbereitung. Hier werden die wichtigsten Herausforder-
ungen der Analyse wie Echtheitsprüfung, botanische No-
menklatur, Variabilität der Pflanzenspezies und -teile 
sowie Aufbereitung hervorgehoben und potenzielle 
Lösungsmöglichkeiten skizziert.
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Summary
Regardless of specific national drug regulations there is 
an international consensus that all TCM drugs must 
meet stipulated high quality standards focusing on au-
thentication, identification and chemical composition. In 
addition, safety of all TCM drugs prescribed by physi-
cians has to be guaranteed. During the 25 years history 
of the TCM hospital Bad Kötzting, 171 TCM drugs under-
went an analytical quality proof including thin layer as 
well as high pressure liquid chromatography. As from 
now mass spectroscopy will also be available as analyti-
cal tool. The findings are compiled and already pub-
lished in three volumes of analytical monographs. One 
more volume will be published shortly, and a fifth vol-
ume is in preparation. The main issues of the analytical 
procedure in TCM drugs like authenticity, botanical no-
menclature, variability of plant species and parts as well 
as processing are pointed out and possible ways to over-
come them are sketched.
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Legislation
When we started this work 25 years ago, we noticed that the 
methods stipulated in the former Chinese Pharmacopoeias were 
not sufficient to meet the high standards of the official German and 
European drug regulatory authorities. Among the various prereq-
uisites for a perfect quality proof of these herbal drugs, authentica-
tion and safety proof took precedence. Identification was at first 
primarily synonymous with the macroscopic and microscopic bo-
tanical authenticity. Since that time, however, chemical composi-
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tion and particularly the complex entities of the low molecular 
constituents have become of greater interest for oral medicinal ap-
plication and thus in evaluating the pharmacological effects and 
therapeutic efficacy of the plant drug extracts obtained by decoc-
tion or other extraction processes.
Independent of the specific national drug regulations for coun-
tries around the world, there is also an international consensus that 
all TCM drugs must meet certain stipulated high quality standards. 
Additionally, it must be guaranteed that all TCM drugs prescribed 
by physicians are safe for patients. The safety proof aims mainly to 
exclude any kind of possible falsifications of the herbal drugs and 
to ensure a limited concentration of heavy metals, aflatoxins and 
defined microbial adulterations.
Applied Methods in Quality Proof
The main method used is the TLC (thin layer chromatography), 
which allows us to visualise the main characteristic constituents as 
coloured TLC photographs. The second, globally used method is 
HPLC (high-pressure liquid chromatography) in the form of a so-
called fingerprint analysis. This technique allows us to detect the 
complex entities of all low-molecular constituents of a plant drug 
extract, with the advantage that the single constituents can be made 
visible in the form of peak profiles. Additionally, the single con-
stituents can be quantified by using online-recordable UV spectra 
with the diode array. It is also possible to gain preliminary infor-
mation as to which chemical structure type the single compounds 
may belong. From that year on, LC-MS (liquid chromatography-
mass spectrometry) is also available for the analysis of plant ex-
tracts whose chemical compositions have previously been investi-
gated only minimally.
Analytical Monographs of Investigated Herbal  
Chinese Drugs
The following volumes were / are going to be published by 
Springer, with financial support from the TCM hospital Bad Kötz-
ting [1–3]:
– Vol. I and II (2011) containing 80 analytical monographs
– Vol. III (2015) containing 23 analytical monographs
– Vol. IV (2016) containing 22 analytical monographs  
(publication scheduled for July 2016)
– Volume V is currently in preparation; the publication is  
scheduled for February/March 2017.
A list of all completed analytical monographs of TCM drugs is 
presented in table 1 and table 2. (All single analytical monographs 
published can be purchased at www.springer.com/de/book/ 
9783709107621). One example for an investigated herbal Chinese 
drug is Artemisia annua L. which recently gained attention in ref-
erence to the Nobel Prize in Medicine in 2015 awarded to the Chi-
nese Professor Dr. Tu Youyou, Beijing (fig. 1) who isolated arte-
misinin as the main constituent of this plant. Today, artemisinin is 
applied in combination with various chemosynthetic drugs (e.g., 
mefloquin) in the treatment of malaria.
Prospects for Improvement of Quality Proof of  
Chinese Herbal Drugs
Authenticity of TCM Drugs Not Definitely Assessed
Some herbal drugs originated from wild collections are not yet 
cultivated under controlled conditions. If they are derived from 
cultivations it must be taken into account that they may originate 
from quite different climate zones and are harvested under differ-
ent conditions. Therefore, their chemical authenticity and homo-
geneity within a defined plant species often cannot be guaranteed. 
We have thus investigated as many herbal drug samples as we were 
able to acquire from different districts, climate zones and markets 
in China, as well as reference drugs from some German herbal 
drug firms that also import herbal drugs from China.
Lacking Information on Plant Parts
In 5–10% of imported plant drugs from China, we do not re-
ceive any specific information about the plant part (flos, fructus, 
semen, folium, cortex or radix and rhizoma) from which they were 
derived. Such drugs are specified as ‘herba’ analogues in the Chi-
nese Pharmacopoeia. For these drug samples, it cannot be expected 
that the TLC and HPLC chemical fingerprints are homogenous. 
Not all parts of a herbal drug contain the same chemical constitu-
ents. The documentation in the corresponding herbal analytical 
monographs confirms this assessment (e.g. Herba Leonuri, vol. II; 
Herba Lysimachiae, vol. III or Herba Violae, vol. IV). Therefore, it 
will be necessary to correct this discrepancy in one of the following 
Chinese Pharmacopoeia publications. Otherwise, it is unlikely to 
reproduce the results of clinical application.
Uncertain Botanical Nomenclature
The non-uniform nomenclature for the same plant from vari-
ous regions of China can cause impermissible confusions or falsifi-
cations. This occurred some years ago when the root of Stephania 
Fig. 1. Tu Youyou.
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Table 1. Contents, alphabetically (Latin nomen-
clature)
Monograph Volume
Acanthopanacis senticosi, Radix I
Achyranthis, Radix III
Aconiti kusnezofii, Radix II
Aconiti lateralis, Radix II
Acori calami, Rhizoma II
Acori tatarinowii, Rhizoma II
Albiziae, Cortex IV
Alismatis, Rhizoma II
Allii Tuberosi, Semen V*
Alpiniae Katsumadai, Semen V*
Amomi rotundus, Fructus I
Ampelopsis, Radix V*
Andrographis, Herba I
Anemarrhenae, Rhizoma I
Angelicae dahuricae, Radix I
Angelicae pubescentis, Radix I
Angelicae sinensis, Radix I
Apocyni veneti, Folium III
Arctii, Fructus IV
Arecae, Pericarpium V*
Armeniacae, Semen V*
Arnebiae, Radix V*
Artemisiae annuae, Herba IV
Artemisiae argyi, Folium IV
Artemisiae scoparia, Herba II
Asari, Herba I
Astragali, Radix I
Atractylodes macrocephalae, Rhizoma I
Atractylodis lanceae, Radix II
Aucklandiae, Radix III
Aurantii immaturus, Fructus V*
Aurantii, Fructus V*
Bambusae, Caulis III
Belamcandae sinensis, Rhizoma I
Bupleuri, Radix I
Camelliae, Folium II
Carthami, Flos II
Cassiae, Semen II
Celosiae, Semen IV
Chaenomelis, Fructus II
Chrysanthemi, Flos V*
Cimicifugae, Rhizoma II
Cinnamomi, Cortex II
Citri reticulatae viride, Pericarpium II
Citri reticulatae, Pericarpium II
Clematidis, Radix I
Cnidii, Fructus II
Codonopsis pilosulae, Rhizoma I
Coptidis, Rhizoma I
Corni, Fructus IV
Corydalis, Rhizoma II
Crataegi, Fructus et Folium III
Curcumae longae, Radix II
Curcumae, Radix II
Curcumae, Rhizoma II
Cuscutae, Semen V*
Monograph Volume
Cyperi, Rhizoma III
Desmodii styracifolii, Herba III
Dictamni, Cortex V*
Dioscoreae hypoglaucae, Rhizoma II
Dioscoreae nipponicae, Rhizoma II
Dioscoreae oppositae, Rhizoma II
Dioscoreae septemlobae, Rhizoma II
Dipsaci, Radix II
Drynariae, Rhizoma I
Ecliptae, Herba I
Ephedrae, Herba IV
Epimedii, Herba II
Equiseti hiemalis, Herba V*
Eriocauli, Flos III
Eucommiae, Cortex II
Evodiae, Fructus I
Forsythiae, Fructus I
Fraxini, Cortex IV
Frittilariae, Bulbus I
Ganoderma II
Gardeniae, Fructus I
Gastrodiae, Rhizoma I
Gentianae macrophyllae, Radix IV
Ginkgo, Folium V*
Ginseng, Radix et Rhizoma II
Glehniae, Radix V*
Glycyrrhizae, Radix et Rhizoma III
Gynostemmatis, Herba III
Houttuyniae cordatae, Herba I
Isatidis, Radix II
Kochiae, Fructus IV
Leonuri, Herba II
Ligustici chuanxiong, Radix I
Ligustri lucidi, Fructus III
Linderae, Radix V*
Lonicerae japonicae, Caulis II
Lonicerae japonicae, Flos II
Lonicerae, Flos II
Luffae, Fructus III
Lycii radicis, Cortex II
Lycii, Fructus II
Lycopi lucidi, Herba I
Lycopodii, Herba III
Lysimachiae christinae, Herba III
Magnoliae officinalis, Cortex I
Magnoliae, Flos II
Mori radicis, Cortex II
Mori, Folium II
Mori, Ramulus IV
Morindae officinalis, Radix III
Moutan, Cortex III
Myrrha V*
Notoginseng, Radix et Rhizoma II
Notopterygii, Rhizoma seu Radix I
Oldenlandiae, Herba III
Olibanum V*
Ophiopogonis, Radix II
Paeoniae albae/rubrae, Radix I
Monograph Volume
Persicae, Semen V*
Peucedani, Radix III
Phellodendri amurensis, Cortex II
Phellodendri chinensis, Cortex II
Picrorhizae, Rhizoma V*
Pinelliae, Rhizoma I
Piperis longi, Fructus II
Plantaginis, Herba IV
Plantaginis, Semen IV
Platycodonis, Radix III
Polygalae, Radix V*
Polygoni avicularis, Herba V*
Polygoni cuspidate, Rhizoma et Radix V*
Polygoni multiflori, Radix I
Poria II
Prunellae, Spica IV
Psoraleae, Fructus IV
Puerariae, Radix I
Quinquefolii, Radix II
Rehmanniae, Radix I
Rhei, Radix et Rhizoma II
Rosae laevigatae, Fructus V*
Salviae miltiorrhizae, Radix et Rhizoma II
Sanguisorbae, Radix V*
Saposhnikoviae, Radix III
Sappan, Lignum IV
Sarcandrae, Herba III
Schisandrae, Fructus I
Schizonepetae, Spica V*
Scrophulariae, Radix I
Scutellariae barbatae, Herba V*
Scutellariae, Radix II
Sesami nigrum, Semen IV
Siegesbeckiae, Herba II
Sinapis albae, Semen IV
Sinomenii, Caulis I
Siraitiae (Momordicae), Fructus III
Solidaginis, Herba V*
Sophorae flavescentis, Radix II
Sophorae immaturus, Flos I
Spatholobi, Caulis III
Stephaniae tetrandrae, Radix I
Trachelospermi, Caulis et Folium V*
Tribuli, Fructus II
Trichosanthis, Fructus IV
Trichosanthis, Radix IV
Trigonellae, Semen V*
Uncariae cum Uncis, Ramulus I
Vaccariae, Semen IV
Verbenae, Herba V*
Violae, Herba IV
Viticis, Fructus IV
Xanthii, Fructus IV
Zanthoxyli, Pericarpium I
Zingiberis, Rhizoma V*
Ziziphi spinosae, Semen I
*Currently in process.
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Table 2. Contents, alphabetically (Chinese names)
Chinese name Volume
Aiye IV
Bai hua she she cao III
Bailian V*
Baishao I
Baixianpi V*
Baizhi I
Baizhu I
Bajitian III
Banlangen II
Banxia I
Banzhilian V*
Beimu I
Beishashen V*
Bianxu V*
Bibo II
Buguzhi IV
Cang’erzi IV
Cangzhu II
Caodoukou V*
Chaihu I
Cha-yeh II
Chenpi II
Cheqiancao IV
Cheqianzi IV
Chishao I
Chuanshanlong II
Chuanxinlian I
Chuanxiong I
Ciwujia I
Dafupi V*
Dahuang II
Danggui I
Dangshen I
Danshen II
Difuzi IV
Digupi II
Dihuang I
Diyu V*
Duhuo I
Duzhong II
Ezhu II
Fangfeng III
Fangji I
Fenbixie II
Fuling II
Fuzi II
Gancao III
Ganjiang V*
Gegen I
Gouqizi II
Gouteng I
Gualou IV
Guangjinqiancao III
Guanhuangbo II
Gujincao III
Gusuibu I
Hehuanpi IV
Heizhima IV
Chinese name Volume
Heshouwu I
Honghua II
Houpo I
Huaihua I
Huaimi I
Huajiao I
Huangbo II
Huanglian I
Huangqi I
Huangqin II
Huhuanglian V*
Huluba V*
Huzhang V*
Jianghuang II
Jiaogulan III
Jiegeng III
Jiezi IV
Jili II
Jingjiesui V*
Jinqiancao III
Jinyingzi V*
Jinyinhua II
Jiucaizi V*
Jixueteng III
Juemingzi II
Juhua V*
Kushen II
Kuxingren V*
Lianqiao I
Lingzhi II
Luobumaya III
Luohanguo III
Luoshiteng V*
Mabiancao V*
Mahuang IV
Maidong II
Manjingzi IV
Mianbixie II
Mohanlian I
Moyao V*
Mudanpi III
Mugua II
Muxiang III
Muzei V*
Niubangzi IV
Niuxi III
Nüzhenzi III
Qianghuo I
Qianhu III
Qingfengteng I
Qinghao IV
Qingpi II
Qingxiangzi IV
Qinjiao IV
Qinpi IV
Rendongteng II
Renshen II
Rougui II
Ruxiang V*
Chinese name Volume
Sangbaipi II
Sangye II
Sangzhi IV
Sanqi II
Shanyao II
Shanyinhua II
Shanzhaye III
Shanzhaye III
Shanzhuyu IV
Sharen I
Shechuangzi II
Shegan I
Shengma II
Shenjincao III
Sichangpu II
Sigualuo III
Suanzaoren I
Sumu IV
Taoren V*
Tianhuafen IV
Tianma I
Tusizi V*
Wangbuliuxing IV
Weilingxian I
Wuweizi I
Wuyao V*
Wuzhuyu I
Xiakucao IV
Xiangfu III
Xinyi II
Xixiancao II
Xixin I
Xiyangshen II
Xuanshen I
Xuduan II
Yanhusuo II
Yimucao II
Yinchen II
Yinxingye V*
Yinyanghuo II
Yizhihuanghua V*
Yuanzhi V*
Yujin II
Yuxingxao I
Zangchangpu II
Zelan I
Zexie II
Zhicaowu II
Zhimu I
Zhiqiao V*
Zhishi V*
Zhizi I
Zhongjiefeng III
Zhuru III
Zicao V*
Zihuadiding IV
*Currently in process.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
2/
20
/2
01
6 
10
:5
1:
35
 A
M
Wagner/Bauer/MelchartForsch Komplementmed 2016;23:16–2020
tetrandra (Hanfangji) was mistaken for the root of Aristolochia 
fangji (Guanfangji). The latter contains the carcinogenic aris-
tolochic acid which can produce severe nephrotoxic side effects. A 
similar Chinese drug is the tetraploid Acorus tatarinowii with a 
high content of carcinogenic β-asarone in contrast to the diploid 
Acorus calamus L., known officially in most Western countries. 
This must also be corrected in one of the next Chinese Pharmaco-
poeias. Meanwhile, special chromatographic methods were devel-
oped and described in the analytical monographs to avoid such 
falsifications.
Great Variability of Plant Species
Several herbal drug monographs of the Chinese Pharmacopoeia 
list more than 2 species or subspecies, and sometimes up to 8 spe-
cies labelled as synonyms, subspecies or subvarieties. It is assumed 
that all species contain the same constituents in the same amount. 
In 20 years of TLC and HPLC fingerprint investigations, we have 
shown that in many cases considerable differences were detectable 
between the single species and the main official drugs. Corre-
spondingly, it may be suggested that a great number of the ‘subspe-
cies’ do not possess the same pharmacological and therapeutic ef-
ficacy. This fact must be taken into consideration.
Processing of TCM Drugs
Apart from simply cutting and cleaning of the raw drugs, the 
Chinese Pharmacopoeia describes many other types of pretreat-
ment or processing that is not considered in Western pharmaco-
poeias. In the Pharmacopoeia of the People’s Republic of China, 
the processing is defined as ‘a unique pharmaceutical technology 
that processes crude drugs according to their individual nature, 
and the requirements of drug dispensing, pharmaceutical prepara-
tion, and clinical use, following the Traditional Chinese Medicine 
theory’. However, in none of the monographs the necessity of spe-
cific processing is substantiated. According to the Chinese Phar-
macopoeia, processing can be achieved primarily through the fol-
lowing methods: roasting and broiling, scalding, calcining, carbon-
ising, steaming, boiling, stewing with wine, vinegar or salt water 
and different kinds of stir baking. In one example, the alkaloid-
containing herbal drugs of Aconitum spp., Aconitum carmichaelii 
and Aconitum kusnezoffii, are treated with salt water, liquorice 
root, black beans and water after scalding by heating at high tem-
perature with sand. The TLC and HPLC fingerprint analysis shows 
that in the processed roots, the alkaloids aconitine and mesaconi-
tine are significantly degraded. Here, the necessity to reduce the 
aconitine content is clear because of its toxicity in higher doses (i.e. 
in an unprocessed form). Therefore, in Western countries such as 
Germany, aconitine preparations are acceptable only in homeo-
pathic dilution form (e.g., as aconitum D6 or D12). This means 
that it is mandatory to limit the proportion of aconitine to a stipu-
lated level. 
As far as the processing methods of the Chinese Pharmacopoeia 
are concerned, they must be replaced by the modern phytochemi-
cal methods demanded by the German and by most European drug 
regulation authorities.
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